Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4.

Dheerendra PC, Sakhuja V, Kohli HS, Jha V.

Indian J Nephrol. 2013 Jul;23(4):271-5. doi: 10.4103/0971-4065.114492.

2.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
3.

Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.

Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2000 Sep;36(3):550-61.

PMID:
10977787
5.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50.

PMID:
11689387
6.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2001 Mar;37(3):532-43.

PMID:
11228177
7.

[German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].

Reichel H, Braun J.

Dtsch Med Wochenschr. 2011 Jan;136(4):123-8. doi: 10.1055/s-0030-1247876. Epub 2010 Dec 21. German.

PMID:
21181622
8.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

9.

Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.

Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM.

Am J Nephrol. 2005 Nov-Dec;25(6):591-5. Epub 2005 Nov 9.

PMID:
16282676
10.

Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Kumar N, Lindberg J, David K, Morris J, Menoyo J.

Am J Nephrol. 2009;29(2):71-8. doi: 10.1159/000151275. Epub 2008 Aug 8.

PMID:
18689981
11.

High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.

Douthat WG, Castellano M, Berenguer L, Guzmán MA, de Arteaga J, Chiurchiu CR, Massari PU, Garay G, Capra R, de La Fuente JL.

Nefrologia. 2013;33(5):657-66. doi: 10.3265/Nefrologia.pre2013.May.12009. English, Spanish.

12.

Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.

Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA; TARGET Investigators.

Nephrol Dial Transplant. 2008 Jul;23(7):2311-8. doi: 10.1093/ndt/gfn026. Epub 2008 Feb 29.

PMID:
18310602
13.

Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.

Sharma A, Marshall TS, Khan SS, Johns B.

Clin Drug Investig. 2014 Feb;34(2):107-15. doi: 10.1007/s40261-013-0151-4. Erratum in: Clin Drug Investig. 2014 Feb;34(2):163.

14.

Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.

Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.

Artif Organs. 2011 Dec;35(12):1186-93. doi: 10.1111/j.1525-1594.2011.01270.x. Epub 2011 Aug 17.

PMID:
21848793
15.

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.

Clin Nephrol. 2001 Oct;56(4):315-23.

PMID:
11680662
16.

Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.

Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.

Ren Fail. 2005;27(2):205-12. Erratum in: Ren Fail. 2005;27(6):805. Ding, Feng [added]; Chen, Nan [added]; Mei, Chang-lin [added]; Qian, Jia-qi [added]; Wang, Xiao-yun [added]; Shi, Wei [added]; Hou, Fan-fan [added]; Li, Xue-wang [added]; Wang, Mei [added]; Chen, Yi-pu [added].

PMID:
15807187
17.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
18.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
19.

A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease.

Qunibi W, Winkelmayer WC, Solomon R, Moustafa M, Kessler P, Ho CH, Greenberg J, Diaz-Buxo JA.

BMC Nephrol. 2011 Feb 16;12:9. doi: 10.1186/1471-2369-12-9.

20.

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB.

Kidney Int. 2011 Jan;79(1):112-9. doi: 10.1038/ki.2010.352. Epub 2010 Sep 22.

Supplemental Content

Support Center